NCT00642629View on ClinicalTrials.gov

A Randomized, Double-blind, Placebo-controlled Clinical Study of the Oral IL-12/23 Inhibitor, STA-5326 Mesylate, Administered to Patients With Rheumatoid Arthritis to Determine Safety, Tolerability, Pharmacokinetic and Synovial Tissue Outcomes

PHASE2CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

December 31, 2005

Conditions
Active, Moderate to Severe Rheumatoid Arthritis
Interventions
DRUG

STA 5326 mesylate

STA 5326 mesylate 100mg taken orally twice a day for 8 weeks with the option to continue at the same dose and frequency for an additional 4 weeks.

DRUG

Placebo

Placebo taken orally twice a day for 8 weeks with the option to continue at the same dose and frequency for an additional 4 weeks.

Trial Locations (1)

Unknown

Academic Medical Center, Amsterdam

All Listed Sponsors
lead

Synta Pharmaceuticals Corp.

INDUSTRY

NCT00642629 - A Randomized, Double-blind, Placebo-controlled Clinical Study of the Oral IL-12/23 Inhibitor, STA-5326 Mesylate, Administered to Patients With Rheumatoid Arthritis to Determine Safety, Tolerability, Pharmacokinetic and Synovial Tissue Outcomes | Biotech Hunter | Biotech Hunter